Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival
JournalJournal of Clinical Investigation
PublisherAmerican Society for Clinical Investigation
MetadataShow full item record
AbstractThe targeted delivery of therapeutic drugs to lymph nodes (LNs) provides an unprecedented opportunity to improve the outcomes of transplantation and immune-mediated diseases. The high endothelial venule is a specialized segment of LN vasculature that uniquely expresses peripheral node addressin (PNAd) molecules. PNAd is recognized by MECA79 mAb. We previously generated a MECA79 mAb-coated microparticle (MP) that carries tacrolimus. Although this MP trafficked to LNs, it demonstrated limited therapeutic efficacy in our transplant model. Here, we have synthesized a nanoparticle (NP) as a carrier of anti-CD3, and optimized the conjugation strategy to coat the NP surface with MECA79 mAb (MECA79-anti- CD3-NP) to enhance LN accumulation. As compared with nonconjugated NPs, a significantly higher quantity of MECA79- NPs accumulated in the draining lymph node (DLN). Many MECA79-NPs underwent internalization by T cells and dendritic cells within the LNs. Short-term treatment of murine cardiac allograft recipients with MECA79-anti-CD3-NP resulted in significantly prolonged allograft survival in comparison with the control groups. Prolonged graft survival following treatment with MECA79-anti-CD3-NP was characterized by a significant increase in intragraft and DLN Treg populations. Treg depletion abrogated the prolongation of heart allograft survival. We believe this targeted approach of drug delivery could redefine the methods of administering immune therapeutics in transplantation. Copyright 2018 American Society for Clinical Investigation. All rights reserved.
SponsorsThis work is in part supported by NIH grant T32-EB016652 (to BB), National Institute of Allergy and Infectious Diseases grants R01-AI126596 and R01-HL141815 (to RA), aa Brigham Research Institute Stepping Strong Innovator Award (to RA), the BWH Health & Technology Innovation Fund (to RA), and National Priorities Research Program (NPRP) grant 9-350-3-074 (to RA).
KeywordDrug Delivery Systems--methods
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85055824754&doi=10.1172%2fJCI120923&partnerID=40&md5=1593ab52d835453b4134d034a8e2837b; http://hdl.handle.net/10713/9728
- Targeted Delivery of Immunomodulators to Lymph Nodes.
- Authors: Azzi J, Yin Q, Uehara M, Ohori S, Tang L, Cai K, Ichimura T, McGrath M, Maarouf O, Kefaloyianni E, Loughhead S, Petr J, Sun Q, Kwon M, Tullius S, von Andrian UH, Cheng J, Abdi R
- Issue date: 2016 May 10
- Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery.
- Authors: Bahmani B, Uehara M, Ordikhani F, Li X, Jiang L, Banouni N, Ichimura T, Kasinath V, Eskandari SK, Annabi N, Bromberg JS, Shultz LD, Greiner DL, Abdi R
- Issue date: 2018 Dec
- Anti-OX40L monoclonal antibody prolongs secondary heart allograft survival based on CD40/CD40L and LFA-1/ICAM-1 blockade.
- Authors: Dai H, Peng F, Lin M, Xia J, Yu S, Lan G, Wang Y, Xie X, Fang C, Corbascio M, Qi Z, Peng L
- Issue date: 2015 Mar
- Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner.
- Authors: Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL
- Issue date: 2000 Jan 1
- Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
- Authors: Lu L, Li W, Zhong C, Qian S, Fung JJ, Thomson AW, Starzl TE
- Issue date: 1999 Sep 27